Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a parallel, two-arm, open-label, multicenter phase IA/IB study of LBH589 (oral
formulation) alone and in combination with docetaxel in patients with progressing hormone
refractory prostate cancer. This study is designed to determine the maximum tolerated dose of
LBH589 as a single agent and in combination with docetaxel and prednisone 5 mg two times a
day , and to characterize the safety, tolerability, biologic activity and pharmacokinetic
profile